Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
4 Large Drug Stocks to Watch as the Industry Recovers
01:32pm, Thursday, 19'th May 2022 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are wor
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
07:05pm, Wednesday, 18'th May 2022 Zacks Investment Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
03:30pm, Tuesday, 17'th May 2022 Zacks Investment Research
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
How to find the best stocks in a bad market using this proven dividend yield strategy
02:18pm, Saturday, 14'th May 2022 MarketWatch
Focus only on blue-chip stocks with strong enough financials to keep paying dividends through thick and thin.
Was This Acquisition a Smart Move for GlaxoSmithKline?
02:00pm, Saturday, 14'th May 2022 The Motley Fool
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
07:00pm, Thursday, 12'th May 2022 Benzinga
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc
Why GSK May Have Bet Too Big on a Pandemic Pipeline
11:57am, Saturday, 07'th May 2022 The Motley Fool
Its late-stage pipeline is heavily weighted toward pandemic treatments.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 Update
05:44am, Saturday, 07'th May 2022 Seeking Alpha
Ken Fisher’s 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Find more details here...
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
03:05pm, Friday, 29'th Apr 2022 Zacks Investment Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
03:10pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
GlaxoSmithKline earnings, revenue beat expectations
07:11am, Wednesday, 27'th Apr 2022 MarketWatch
Earnings per share were 35.6 pence in the quarter, a jump from 21.3 pence in the same quarter the year prior. Adjusted earnings per share--a closely-watched metric--were 32.8 pence, which the company
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
03:44pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
GlaxoSmithKline (GSK) Stock Moves -0.33%: What You Should Know
09:45pm, Thursday, 21'st Apr 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.69, marking a -0.33% move from the previous day.
